Loading...
Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE).
Reck, M Thomas, M Kropf-Sanchen, C Mezger, J Socinski, M A Depenbrock, H Soldatenkova, V Brown, J Krause, T Thatcher, Nick
Reck, M
Thomas, M
Kropf-Sanchen, C
Mezger, J
Socinski, M A
Depenbrock, H
Soldatenkova, V
Brown, J
Krause, T
Thatcher, Nick
Citations
Altmetric:
Abstract
In the SQUIRE study, adding the anti-epidermal growth factor receptor (EGFR) IgG1 antibody necitumumab to first-line gemcitabine and cisplatin (GC + N) in advanced squamous non-small-cell lung cancer (sqNSCLC) significantly improved overall survival (OS); the safety profile was acceptable. We explored data for the German subpopulation (N = 96) of SQUIRE patients with EGFR-expressing tumors.
Affiliation
Description
Date
2016
Publisher
Collections
Files
Keywords
Type
Article
Citation
Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). 2016, 39(9): 539-47 Oncol Res Treat